Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico - 1 May 2020

Isla D, de Castro J, García-Campelo R, Lianes P, Felip E, Garrido P, Paz-Ares L, Trigo J M

Abstract excerpt

PURPOSE: Immunotherapy-based approaches are standard first-line treatments for advanced/metastatic lung cancer or for chemoradiotherapy consolidation in locally advanced disease. Uncertainty on how to treat patients at disease progression prompted us to develop a consensus document on post-immunotherapy options in Spain for patients with advanced wild-type lung adenocarcinoma. METHODS: After extensive literature...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Decision-Making

Share to Consensus

Share to Docetaxel

Share to Immunotherapy

Share to Indoles

Source

Identifiers

PMID: 31368078
DOI: 10.1007/s12094-019-02191-y

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus.PMID 31368078Read ↗

Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus.Semantic proximity Read ↗

Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the 'panacea' for all patients?Semantic proximity Read ↗

Update in Immunotherapy for Advanced Non-small Cell Lung Cancer: Treatment Sequencing and Best ChoicesSemantic proximity Read ↗

Comparison of efficacy and safety of first-line treatment options for unresectable stage III non-small cell lung cancer: a retrospective analysisSemantic proximity Read ↗

Immunotherapy in Advanced NSCLC Without Driver Mutations: Available Therapeutic Alternatives After Progression and Future Treatment Options.Semantic proximity Read ↗

Non–Small Cell Lung Cancer Metastatic Without Oncogenic AlterationsSemantic proximity Read ↗

Consensus on the diagnosis and treatment of unresectable stage III driver gene-positive non-small cell lung cancer.Semantic proximity Read ↗

Second-Line Chemotherapy and Beyond for Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Integrating clinico-pathological features and longitudinal liquid biopsy results to predict clinical benefit from immune checkpoint Inhibitors in advanced Non-Small Cell Lung Cancer patientsSemantic proximity Read ↗

Novel agents in second-line therapy for EGFR wild-type Advanced Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Immunotherapy for patients with advanced non-small cell lung cancer harboring oncogenic driver alterations other than EGFR: a multicenter real-world analysisSemantic proximity Read ↗

The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.